BR112022019846A2 - Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos - Google Patents
Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostosInfo
- Publication number
- BR112022019846A2 BR112022019846A2 BR112022019846A BR112022019846A BR112022019846A2 BR 112022019846 A2 BR112022019846 A2 BR 112022019846A2 BR 112022019846 A BR112022019846 A BR 112022019846A BR 112022019846 A BR112022019846 A BR 112022019846A BR 112022019846 A2 BR112022019846 A2 BR 112022019846A2
- Authority
- BR
- Brazil
- Prior art keywords
- ccdp12
- rms
- methods
- reduce
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODO DE TRATAMENTO DE ESCLEROSE MÚLTIPLA RECORRENTE (RMS), MÉTODOS PARA REDUZIR A TAXA DE RECORRÊNCIA ANUALIZADA (ARR), REDUZIR O RISCO DE EXPERIMENTAR CCDP12 E AUMENTAR O TEMPO ATÉ O INÍCIO DE CCDP12 E COMPOSTOS. São fornecidos no presente documento métodos de tratamento de Esclerose Múltipla Recorrente (RMS) em um indivíduo em necessidade do mesmo, por meio da administração ao indivíduo cerca de 200 mg de fenebrutinibe duas vezes ao dia, ou uma quantidade equivalente de um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019846A2 true BR112022019846A2 (pt) | 2022-11-22 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019846A BR112022019846A2 (pt) | 2020-04-03 | 2021-04-01 | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230149395A1 (pt) |
| EP (1) | EP4125906A1 (pt) |
| JP (1) | JP2023520469A (pt) |
| KR (1) | KR20220163986A (pt) |
| CN (1) | CN115916205A (pt) |
| AU (1) | AU2021249129A1 (pt) |
| BR (1) | BR112022019846A2 (pt) |
| CA (1) | CA3177390A1 (pt) |
| CL (1) | CL2022002699A1 (pt) |
| IL (1) | IL296990A (pt) |
| MX (1) | MX2022012310A (pt) |
| TW (1) | TW202203925A (pt) |
| WO (1) | WO2021202825A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| JP6577143B2 (ja) | 2016-02-29 | 2019-09-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 |
-
2021
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko unknown
- 2021-04-01 TW TW110112266A patent/TW202203925A/zh unknown
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en active Application Filing
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 US US17/995,259 patent/US20230149395A1/en active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115916205A (zh) | 2023-04-04 |
| MX2022012310A (es) | 2022-10-27 |
| AU2021249129A1 (en) | 2022-10-20 |
| WO2021202825A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| EP4125906A1 (en) | 2023-02-08 |
| CL2022002699A1 (es) | 2023-03-31 |
| JP2023520469A (ja) | 2023-05-17 |
| IL296990A (en) | 2022-12-01 |
| CA3177390A1 (en) | 2021-10-07 |
| TW202203925A (zh) | 2022-02-01 |
| KR20220163986A (ko) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Di Caprio et al. | Anti‐inflammatory properties of low and high doxycycline doses: an in vitro study | |
| BR112022019846A2 (pt) | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| EP4306542A3 (en) | Treatment of lag-3 positive tumors | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| ATE174785T1 (de) | Behandlung von akne oder von folliculitis barbae | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2020007384A (es) | Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado. | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| MX2022004056A (es) | Composicion novedosa para el cuidado de la piel. | |
| MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. | |
| DE69624355D1 (de) | Verfahren zur arzneistoffabgabe mittels gentherapie | |
| BR112023021131A2 (pt) | Tratamento de tremor essencial | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| BRPI0716929A8 (pt) | tratamento de esclerose múltipla com campath-1h | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2022004050A (es) | Composicion novedosa para el cuidado de la piel. | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| MX2022014466A (es) | Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. | |
| WO2021011875A8 (en) | Compositions and methods for treating skin conditions |